Home  About Journal Instructions for Authors Editorial Board Subscribe Advertisement Messages Board Contact Us 中文

CJAP ›› 2022, Vol. 38 ›› Issue (2): 149-153.doi: 10.12047/j.cjap.6202.2022.019

• ORIGINAL ARTICLES • Previous Articles     Next Articles

Protective effects of dexamethasone combined with valsartan on chronic obstructive pulmonary disease in mice and its mechanism

LI Yong-rong1, XIE Hai-bin2, LI Hong3, SUN Jie4△   

  1. 1. Department of Lung Disease, Affiliated Hospital of Gansu University of Traditional Chinese Medicine, Lanzhou 730020;
    2. Department of Geriatrics, Affiliated Hospital of Gansu University of Traditional Chinese Medicine, Lanzhou 730020;
    3. Department of Respiratory, Luohu District Hospital of Traditional Chinese Medicine, Shenzhen 518001;
    4. Department of Cardiorespiratory Rehabilitation, the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou 510405, China
  • Received:2021-04-08 Revised:2022-03-26 Online:2022-03-28 Published:2022-08-29

Abstract: Objective: To investigate the possible protective effects of combined dexamethasone and valsartan against cigarette induced chronic obstructive pulmonary disease (COPD) in mice. Methods: Forty C57BL/6 mice were randomly divided into control group, COPD group, dexamethasone treated group, valsartan treated group and dexamethasone + valsartan combined treatment group, with 8 mice in each group. Mice in COPD group were exposed to cigarette for 8 weeks. On the basis of cigarette exposure, mice in dexamethasone treated group were intraperitoneally injected with dexamethasone (2 mg / kg) before cigarette exposure for 5-8 weeks. Mice in valsartan treated group were intraperitoneally injected with valsartan (30 mg/kg) before cigarette exposure for 1-8 weeks. Dexamethasone (2 mg/kg) and valsartan (30 mg/kg) were injected intraperitoneally into mice in the dexamethasone + valsartan combined treatment group. After 8 weeks, the lung tissues and bronchoalveolar lavage fluid (BALF) of mice in each group were collected. The pathological score of lung tissue was evaluated. The activities of superoxide dismutase(SOD) and matrix metalloproteinase-9 (MMP-9), and the contents of malondialdehyde (MDA), intracellular adhesion molecule-1 (ICAM-1), C-reactive protein (CRP) and nitric oxide (NO) in BALF were determined. Results: Compared with the control group, COPD mice had emphysema and alveolar congestion, the levels of MDA, ICAM-1, MMP-9, CRP and lymphocytes in BALF were increased, while the levels of SOD, macrophages and NO were decreased (all P<0.05). Compared with COPD group, there was no significant improvement in emphysema and alveolar congestion, the levels of SOD and NO in BALF were increased, and the levels of MDA, lymphocytes and macrophages were decreased in dexamethasone or valsartan group (all P<0.05). Compared with dexamethasone or valsartan group, the dexamethasone + valsartan combined treatment was more effective in preventing pulmonary emphysema and alveolar congestion caused by cigarette smoke. The levels of MDA, ICAM-1, MMP-9, CRP and lymphocyte in BALF were decreased, while the levels of SOD, macrophage and NO were increased (all P<0.05). Conclusion: Compared with dexamethasone or valsartan, dexamethasone combined with valsartan has a more effective protective effect in COPD mice by inhibiting oxidative stress and inflammation.

Key words: dexamethasone, valsartan, chronic obstructive pulmonary disease, mice

CLC Number: 

Contact Email:editor@cjap.ac.cn
Copyright © 2015 CJAP, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd